Melanoma ex naevo: A study of the associated naevus

Melanoma Research

Volumn 13, Issue 2, 2003, Pages 213-217

  Bogdan, Inja ^a   Smolle, Josef ^b   Kerl, Helmut ^b   Burg, Günther ^a   Böni, Roland ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

9p21; Loss of heterozygosity; Melanoma; Naevi; p16

Indexed keywords

DNA MARKER;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CHROMOSOME 9P; CHROMOSOME DELETION; CHROMOSOME LOSS; CHROMOSOME MICRODISSECTION; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; NEVUS; PRECANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ALLELES; CHROMOSOMES, HUMAN, PAIR 9; DNA; DYSPLASTIC NEVUS SYNDROME; GENE DELETION; GENES, P16; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; MELANOMA; MICROSATELLITE REPEATS; NEVUS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PRECANCEROUS CONDITIONS; SKIN NEOPLASMS;

EID: 0037565693     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200304000-00018     Document Type: Article

References (38)

1. Garbe C, Kruger S, Stadler R, Guggenmoos Holzmann I, Orfanos CE. Markers and relative risk in a German population for developing malignant melanoma. Int J Dermatol 1989; 28:517-523.
2. MacKie RM, Freudenberger T, Aitchison TC. Personal risk-factor chart for cutaneous melanoma. Lancet 1989; ii:487-490.
3. Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997; 277:1439-1444.
4. Schneider JS, Moore DH II, Sagebiel RW. Risk factors for melanoma incidence in prospective follow-up. The importance of atypical (dysplastic) nevi. Arch Dermatol 1994; 130:1002-1007.
5. Carli P, Biggeri A, Giannotti B. Malignant melanoma in Italy: risks associated with common and clinically atypical melanocytic nevi. J Am Acad Dermatol 1995; 32:734-739.
6. Snels DG, Hille ET, Gruis NA, Bergman W. Risk of cutaneous malignant melanoma in patients with nonfamilial atypical nevi from a pigmented lesions clinic. J Am Acad Dermatol 1999; 40:686-693.
7. Carli P, Massi D, Santucci M, Biggeri A, Giannotti B. Cutaneous melanoma histologically associated with a nevus and melanoma de novo have a different profile of risk: results from a case-control study. J Am Acad Dermatol 1999; 40:549-557.
8. Sagebiel RW. Melanocytic nevi in histologic association with primary cutaneous melanoma of superficial spreading and nodular types: effect of tumor thickness. J Invest Dermatol 1993; 100:322S-325S.
9. Stolz W, Schmoeckel C, Landthaler M, Braun Falco O. Association of early malignant melanoma with nevocytic nevi. Cancer 1989; 63:550-555.
10. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-767.
11. Clark WH. Tumour progression and the nature of cancer. Br J Cancer 1991; 64:631-644.
12. Clark WH Jr, Elder DE, Guerry DT, Epstein MN, Greene MH, Van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984; 15:1147-1165.
13. Smolle J, Kaddu S, Kerl H. Non-random spatial association of melanoma and nevi - a morphometric analysis. Melanoma Res 1999; 9:407-412.
14. Massi D, Carli P, Franchi A, Santucci M. Naevus-associated melanomas: cause or chance? Melanoma Res 1999; 9:85-91.
15. Urso C, Giannotti V, Reali UM, Giannotti B, Bondi R. Spatial association of melanocytic naevus and melanoma. Melanoma Res 1991; 1:245-249.
16. Harley S, Walsh N, A new look at nevus-associated melanomas. Am J Dermatopathol 1996; 18:137-141.
17. Kang S, Barnhill RL, Mihm MC Jr, Fitzpatrick TB, Sober AJ. Melanoma risk in individuals with clinically atypical nevi. Arch Dermatol 1994; 130:999-1001.
18. Halpern AC, Guerry D IV, Elder DE, Clark WH Jr, Synnestvedt M, Norman S, Ayerle R. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study. Arch Dermatol 1991; 127:995-999.
19. Park WS, Vortmeyer AO, Pack S, Duray PH, Boni R, Guerami AA, et al. Allelic deletion at chromosome 9p21 (p16) and 17p13(p53) in micro-dissected sporadic dysplastic nevus. Hum Pathol 1998; 29:127-130.
20. Elder DE, Goldman LI, Goldman SC, Greene MH, Clark WH Jr. Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer 1980; 46:1787-1794.
21. Nordlund JJ, Kirkwood J, Forget BM, Scheibner A, Albert DM, Lerner E, Milton GW. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res 1985; 45:1855-1861.
22. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264:436-440.
23. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54:5547-5551.
24. Gruis NA, Weaver-Feldhaus J, Liu Q, Frye C, Eeles R, Orlow I, et al. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 1995; 146:1199-1206.
25. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368:753-756.
26. Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, et al. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 1995; 10:1061-1067.
27. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995; 11:210-212.
28. Ackerman AB, Milde P. Naming acquired melanocytic nevi. Common and dysplastic, normal and atypical, or Unna, Miescher, Spitz, and Clark? Am J Dermatopathol 1992; 14:447-453.
29. Ackerman AB, Magana Garcia M. Naming acquired melanocytic nevi. Unna's, Miescher's, Spitz's, Clark's. Am J Dermatopathol 1990; 12:193-209.
30. Healy E, Belgaid CE, Takata M, Vahlquist A, Rehman I, Rigby H, Rees JL. Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res 1996; 56:589-593.
31. Böni R, Matt D, Vortmeyer A, Burg G, Zhuang Z. Chromosomal allele loss in primary cutaneous melanoma is heterogeneous and correlates with proliferation. J Invest Dermatol 1998; 110:215-217.
32. Healy E, Belgaid CE, Takata M, Harrison D, Zhu NW, Burd DAR, et al. Prognostic significance of allelic losses in primary melanoma. Oncogene 1998; 16:2213-2218.
33. Herbst RA, Larson A, Weiss J, Cavenee WK, Hampton GM, Arden KC. A defined region of loss of heterozygosity at 11q23 in cutaneous malignant melanoma. Cancer Res 1995; 55:2494-2496.
34. Walker GJ, Palmer JM, Walters MK, Nancarrow DJ, Parsons PG, Hayward NK. Simple tandem repeat allelic deletions confirm the preferential loss of distal chromosome 6q in melanoma. Int J Cancer 1994; 58:203-206.
35. Bale SJ, Dracopoli NC, Tucker MA, Clark WH Jr, Fraser MC, Stanger BZ, et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 1989; 320:1367-1372.
36. Cowan JM, Halaban R, Francke U. Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. J Natl Cancer Inst 1988; 80:1159-1164.
37. Dreyling MH, Bohlander SK, Le Beau MM, Olopade OI. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood 1995; 86:1931-1938.
38. Hussein MR, Woods GS. Molecular aspects of melanocytic dysplastic nevi. J Mol Diagn 2002; 4:71-80.